Loading clinical trials...
Loading clinical trials...
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Conditions
Interventions
ZW251
Locations
23
United States
UCSF Comprehensive Cancer Center
San Francisco, California, United States
University of California Los Angeles - Cancer Care - Santa Monica (UCLA)
Santa Monica, California, United States
Norton Cancer Institute
Louisville, Kentucky, United States
START Midwest
Grand Rapids, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
October 21, 2025
Primary Completion Date
September 1, 2027
Completion Date
May 1, 2028
Last Updated
April 14, 2026
NCT05969860
NCT06427941
NCT04308330
NCT06503146
NCT06811116
NCT06066138
Lead Sponsor
Zymeworks BC Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions